Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Enobosarm

PLATEAU

Veru Inc · Phase 2 · Active, not recruiting · Enrollment 239

NCT07446998

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Subcutaneous injectable semaglutide and oral enobosarm 3mgn/rn/rn/rn/r
Subcutaneous injectable semaglutide and oral Placebon/rn/rn/rn/r

Not shown

  • Subcutaneous injectable semaglutide and oral enobosarm 3mg: endpoint not reported
  • Subcutaneous injectable semaglutide and oral Placebo: endpoint not reported